Related references
Note: Only part of the references are listed.Interferon alpha for Treatment of Chronic Myeloid Leukemia
Bengt Simonsson et al.
CURRENT DRUG TARGETS (2011)
Pegylated IFN-alpha 2a combined to imatinib mesylate 600 mg daily can induce complete cytogenetic and molecular responses in a subset of chronic phase CML patients refractory to IFN alone or to imatinib 600 mg daily alone
Franck E. Nicolini et al.
LEUKEMIA RESEARCH (2011)
Anti-Leukemia Activity of In Vitro-Expanded Human Gamma Delta T Cells in a Xenogeneic Ph+ Leukemia Model
Gabrielle M. Siegers et al.
PLOS ONE (2011)
Mono/oligoclonal T and NK cells are common in chronic myeloid leukemia patients at diagnosis and expand during dasatinib therapy
Anna Kreutzman et al.
BLOOD (2010)
Immunoprofiling of patients with chronic myeloid leukemia at diagnosis and during tyrosine kinase inhibitor therapy
Peter Rohon et al.
EUROPEAN JOURNAL OF HAEMATOLOGY (2010)
The response to imatinib and interferon-α is more rapid than the response to imatinib alone: a retrospective analysis of 495 Philadelphia-positive chronic myeloid leukemia patients in early chronic phase
Francesca Palandri et al.
HAEMATOLOGICA-THE HEMATOLOGY JOURNAL (2010)
Sustained Molecular Response With Interferon Alfa Maintenance After Induction Therapy With Imatinib Plus Interferon Alfa in Patients With Chronic Myeloid Leukemia
Andreas Burchert et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
Imatinib plus Peginterferon Alfa-2a in Chronic Myeloid Leukemia.
Claude Preudhomme et al.
NEW ENGLAND JOURNAL OF MEDICINE (2010)
Dasatinib versus Imatinib in Newly Diagnosed Chronic-Phase Chronic Myeloid Leukemia
Hagop Kantarjian et al.
NEW ENGLAND JOURNAL OF MEDICINE (2010)
Nilotinib versus Imatinib for Newly Diagnosed Chronic Myeloid Leukemia
Giuseppe Saglio et al.
NEW ENGLAND JOURNAL OF MEDICINE (2010)
PR1-Specific T Cells Are Associated with Unmaintained Cytogenetic Remission of Chronic Myelogenous Leukemia After Interferon Withdrawal
Shreya Kanodia et al.
PLOS ONE (2010)
Primitive quiescent CD34+ cells in chronic myeloid leukemia are targeted by in vitro expanded natural killer cells, which are functionally enhanced by bortezomib
Agnes S. M. Yong et al.
BLOOD (2009)
Does chemotherapy modify the immune surveillance of hematological malignancies?
A. J. Barrett et al.
LEUKEMIA (2009)
Six-year follow-up of patients receiving imatinib for the first-line treatment of chronic myeloid leukemia
A. Hochhaus et al.
LEUKEMIA (2009)
Clonal expansion of T/NK-cells during tyrosine kinase inhibitor dasatinib therapy
S. Mustjoki et al.
LEUKEMIA (2009)
CD8+ memory T cells predominate over naïve T cells in therapy-free CML patients with sustained major molecular response
Kensuke Usuki et al.
LEUKEMIA RESEARCH (2009)
IFNα activates dormant haematopoietic stem cells in vivo
Marieke A. G. Essers et al.
NATURE (2009)
Natural killer and γδ T cells in haematological malignancies: enhancing the immune effectors
Jerome Rey et al.
TRENDS IN MOLECULAR MEDICINE (2009)
Clinical evaluation of BCR-ABL peptide immunisation in chronic myeloid leukaemia: results of the EPIC study
J. M. Rojas et al.
LEUKEMIA (2007)
Rapid natural killer cell recovery determines outcome after T-cell-depleted HLA-identical stem cell transplantation in patients with myeloid leukemias but not with acute lymphoblastic leukemia
B. N. Savani et al.
LEUKEMIA (2007)
Imatinib mesylate discontinuation in patients with chronic myelogenous leukemia in complete molecular remission for more than 2 years
Philippe Rousselot et al.
BLOOD (2007)
NK cells that are activated by CXCL10 can kill dormant tumor cells that resist CTL-mediated lysis and can express B7-H1 that stimulates T cells
A Saudemont et al.
BLOOD (2005)
Functional leukemia-associated antigen-specific memory CD8+ T cells exist in healthy individuals and in patients with chronic myelogenous leukemia before and after stem cell transplantation
K Rezvani et al.
BLOOD (2003)
Interferon-alpha, but not the ABL-kinase inhibitor imatinib (STI571), induces expression of myeloblastin and a specific T-cell response in chronic myeloid leukemia
A Burchert et al.
BLOOD (2003)
Follow-up of complete cytogenetic remission in patients with chronic myeloid leukemia after cessation of interferon alfa
FX Mahon et al.
JOURNAL OF CLINICAL ONCOLOGY (2002)
Human gamma delta T cells: a nonredundant system in the immune-surveillance against cancer
M Ferrarini et al.
TRENDS IN IMMUNOLOGY (2002)
Chronic myeloid leukemia and interferon-α:: a study of complete cytogenetic responders
F Bonifazi et al.
BLOOD (2001)
Expression of interferon consensus sequence binding protein induces potent immunity against BCR/ABL-induced leukemia
M Deng et al.
BLOOD (2001)
Evidence that specific T lymphocytes may participate in the elimination of chronic myelogenous leukemia
JJ Molldrem et al.
NATURE MEDICINE (2000)
Share Paper
